TY - JOUR
T1 - Prevention and Treatment of Cancer-Related Infections, Version 3.2024
AU - Baden, Lindsey Robert
AU - Swaminathan, Sankar
AU - Almyroudis, Nikolaos G.
AU - Angarone, Michael
AU - Baluch, Aliyah
AU - Barros, Nicolas
AU - Buss, Brian
AU - Cohen, Stuart
AU - Cooper, Brenda
AU - Chiang, Augusto Dulanto
AU - El Boghdadly, Zeinab
AU - Gregg, Kevin
AU - Hakim, Hana
AU - Ho, Dora
AU - Khawaja, Fareed
AU - Lee, Rachael
AU - Lee, Francesca
AU - Logan, Cathy
AU - Manley, Kristen
AU - Multani, Ashrit
AU - Pande, Anupam
AU - Pergam, Steven
AU - Pisano, Jennifer
AU - Saullo, Jennifer
AU - Schuster, Mindy
AU - Seo, Susan K.
AU - Shoham, Shmuel
AU - Taplitz, Randy
AU - Topal, Jeffrey
AU - Wilson, John W.
AU - Zimmer, Andrea
AU - Cassara, Carly J.
AU - Kumar, Rashmi
AU - Diwan, Zeenat
N1 - Publisher Copyright:
© 2024 Harborside Press. All rights reserved.
PY - 2024/11
Y1 - 2024/11
N2 - There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.
AB - There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.
UR - http://www.scopus.com/inward/record.url?scp=85209346365&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.0056
DO - 10.6004/jnccn.2024.0056
M3 - Article
C2 - 39536464
AN - SCOPUS:85209346365
SN - 1540-1405
VL - 22
SP - 617
EP - 644
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -